Trial site
Chonbuk National University Hospital
- 9running trials
- 7closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Conditions
- Coronary artery disease5 trials
- Acute lymphoblastic leukaemia1 trial
- Alopecia areata1 trial
- Chronic lymphocytic leukaemia1 trial
- Chronic myeloid leukaemia1 trial
- Deep vein thrombosis and pulmonary embolism1 trial
- Diffuse large B-cell lymphoma1 trial
- Lung cancer1 trial
- Multiple myeloma1 trial
- Schizophrenia1 trial
- Spinal muscular atrophy1 trial
- Type 2 diabetes1 trial
- Phase
- Phase 33 trials
- Phase 1/22 trials
- Phase 42 trials
- Phase 11 trial
- Phase 21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting5 trials
- Completed5 trials
- Recruiting3 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- Seung-Jung Park2 trials
- Arcus Biosciences, Inc.1 trial
- Biogen1 trial
- Boehringer Ingelheim1 trial
- Celgene1 trial
- and 10 more
Running trials
Not yet recruiting
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
Recruiting
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Active, not recruiting
Active, not recruiting
Timing of FFR-guided PCI for Non-IRA in STEMI and MVD (OPTION-STEMI)
Active, not recruiting
Active, not recruiting
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Active, not recruiting
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Recruiting
Recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Coronary artery disease2 recruiting
- Deep vein thrombosis and pulmonary embolism1 recruiting
- Type 2 diabetes1 recruiting
Closed trials
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Completed
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
Completed
Completed
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Completed
Terminated
Completed
Site data: ClinicalTrials.govUpdated 13 Nov 2026